Maurizio Zangari

Summary

Affiliation: University of Arkansas for Medical Sciences
Country: USA

Publications

  1. ncbi request reprint Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation
    Maurizio Zangari
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA
    Br J Haematol 126:715-21. 2004
  2. pmc High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients
    Mauricio Pineda-Roman
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Cancer 112:1754-64. 2008
  3. ncbi request reprint Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 138:176-85. 2007
  4. ncbi request reprint Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning
    Choon Kee Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Exp Hematol 31:73-80. 2003
  5. ncbi request reprint Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival
    Maurizio Zangari
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Clin Lymphoma 4:32-5. 2003
  6. ncbi request reprint Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients
    Maurizio Zangari
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Am J Hematol 82:831-3. 2007
  7. ncbi request reprint DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma
    Choon Kee Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Slot 776, 4301 West Markham, Little Rock, AR 72205, USA
    J Clin Oncol 21:2732-9. 2003
  8. ncbi request reprint Thalidomide and hematopoietic-cell transplantation for multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    N Engl J Med 354:1021-30. 2006
  9. ncbi request reprint Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients
    Maurizio Zangari
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Blood Coagul Fibrinolysis 18:595-8. 2007
  10. ncbi request reprint Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease
    Mauricio Pineda-Roman
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 136:393-9. 2007

Collaborators

Detail Information

Publications63

  1. ncbi request reprint Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation
    Maurizio Zangari
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA
    Br J Haematol 126:715-21. 2004
    ..The rate of DVT recurrence observed in our study upon thalidomide resumption was sufficiently low to allow its continuation in patients who may benefit from this therapeutic intervention...
  2. pmc High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients
    Mauricio Pineda-Roman
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Cancer 112:1754-64. 2008
    ..In this report, the authors describe their collective experience with melphalan-based autotransplants since the inception of their program at the University of Arkansas for Medical Sciences in 1989...
  3. ncbi request reprint Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 138:176-85. 2007
    ..Results of this phase-2 study demonstrated that bortezomib could be safely combined with multi-agent chemotherapy, effecting near-complete remission status and 2-year survival rates in more than 80% of patients...
  4. ncbi request reprint Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning
    Choon Kee Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Exp Hematol 31:73-80. 2003
    ..The aim of this study was to identify prognostic factors for outcome of high-risk patients with multiple myeloma after allogeneic transplantation prepared by reduced intensity conditioning (RIC)...
  5. ncbi request reprint Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival
    Maurizio Zangari
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Clin Lymphoma 4:32-5. 2003
    ..002), and creatinine level > or = 2 mg/dL (P < 0.001). However, the development of DVT did not adversely affect survival when examined as a time-dependent variable and adjusted for standard risk features (hazard ratio, 0.8; P = 0.162)...
  6. ncbi request reprint Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients
    Maurizio Zangari
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Am J Hematol 82:831-3. 2007
    ..01). Markers of osteoblastic activation may predict quality and duration of response in multiple myeloma. In addition, our data suggest that bone anabolism could inhibit myeloma growth...
  7. ncbi request reprint DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma
    Choon Kee Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Slot 776, 4301 West Markham, Little Rock, AR 72205, USA
    J Clin Oncol 21:2732-9. 2003
    ..To improve outcome in previously treated patients (at least two cycles of standard therapy) with multiple myeloma, thalidomide was combined with cytotoxic chemotherapy as induction therapy...
  8. ncbi request reprint Thalidomide and hematopoietic-cell transplantation for multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    N Engl J Med 354:1021-30. 2006
    ..High-dose therapy with melphalan can prolong survival among patients with multiple myeloma. We assessed whether the addition of thalidomide, which has activity against advanced and refractory myeloma, would further improve survival...
  9. ncbi request reprint Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients
    Maurizio Zangari
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Blood Coagul Fibrinolysis 18:595-8. 2007
    ..02). Our observation suggests a possible beneficial effect of anticoagulation on survival in patients treated for myeloma...
  10. ncbi request reprint Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease
    Mauricio Pineda-Roman
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 136:393-9. 2007
    ..In comparison with U-MM, E-MM evolved from MGUS/SMM was associated with lower CR rate without adversely affecting survival. In contrast, CR was an independent favourable feature for survival in U-MM...
  11. pmc Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2
    Mauricio Pineda-Roman
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 140:625-34. 2008
    ..Our data strongly suggest that the addition of bortezomib in TT3 was accountable for its superior performance rather than greater compliance with protocol completion as a result of greater dose-density in TT3 vs. TT2...
  12. ncbi request reprint Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies
    Bart Barlogie
    Medicine and Pathology, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 107:2633-8. 2006
    ..The favorable effects of CR and rapidly sequenced second transplantation attest to the validity of a melphalan dose-response effect in myeloma...
  13. ncbi request reprint Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics
    John D Shaughnessy
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 137:530-6. 2007
    ....
  14. pmc Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
    Blood 112:3115-21. 2008
    ..008). Because two thirds of patients without CAs have remained alive at 7 years, the presently emerging separation in favor of thalidomide may eventually reach statistical significance as well...
  15. pmc Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham, Little Rock, AR 72205, USA
    Blood 111:94-100. 2008
    ..While the risk of MDS-CAs was low and clinical MDS occurred infrequently, monitoring after post-HDT consolidation chemotherapy appears warranted...
  16. ncbi request reprint Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II
    John Shaughnessy
    Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 120:44-52. 2003
    ..02 and 0.1 respectively) and should be part of the initial work-up of patients with MM...
  17. ncbi request reprint Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 119:164-8. 2002
    ..Other approaches may be required to improve survival in multiple myeloma...
  18. ncbi request reprint Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications
    Ronald Walker
    Department of Radiology, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    J Clin Oncol 25:1121-8. 2007
    ..Magnetic resonance imaging (MRI) permits the detection of diffuse and focal bone marrow infiltration in the absence of osteopenia or focal osteolysis on standard metastatic bone surveys (MBSs)...
  19. ncbi request reprint Treatment of multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 103:20-32. 2004
    ..Fundamental and clinical research should, therefore, focus on the molecular and biologic mechanisms of treatment failure in the high-risk subgroup...
  20. pmc Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1
    Maurizio Zangari
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 141:433-44. 2008
    ..These results provide a basis for the prospective evaluation of the consolidation strategy in a randomized clinical trial design...
  21. ncbi request reprint Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 123:484-9. 2003
    ..In conclusion, a sizeable fraction of myeloma patients relapsing after tandem autotransplants without poor-risk features enjoyed meaningful survival prolongation when appropriately treated...
  22. pmc RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma
    Siqing Wang
    The Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham, Little Rock, AR, USA
    Blood 114:600-7. 2009
    ..These findings provide a rationale for RA-based therapy in aggressive RARalpha2(+) MM...
  23. pmc The Arkansas approach to therapy of patients with multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, UAMS, Little Rock, AR, USA
    Best Pract Res Clin Haematol 20:761-81. 2007
    ....
  24. ncbi request reprint Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy
    Maurizio Zangari
    Central Arkansas Veterans Healthcare System and University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Blood 100:1168-71. 2002
    ..02) was observed; this association was confirmed on multivariate analysis. MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT...
  25. ncbi request reprint Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 118:1041-7. 2002
    ..Furthermore, these parameters in combination with easily obtained pretransplant levels of beta-2 microglobulin and albumin define three groups of MM patients with clearly distinct outcomes...
  26. ncbi request reprint Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Clin Lymphoma Myeloma 6:469-74. 2006
    ..Complete response has been considered a surrogate for favorable long-term outcome in multiple myeloma. Data on the impact of the duration of response on prognosis are lacking...
  27. ncbi request reprint Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia
    Ashraf Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, USA
    Leuk Lymphoma 43:1267-71. 2002
    ..The use of thalidomide should be carefully assessed in relapsed multiple myeloma patients with clinical and cytogenetic evidence of t-MDS...
  28. ncbi request reprint Response to bortezomib and activation of osteoblasts in multiple myeloma
    Maurizio Zangari
    University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Clin Lymphoma Myeloma 7:109-14. 2006
    ..0001). This clinical observation has been confirmed in an experimental mouse model for primary human myeloma. The consequences of increased bone anabolism on myeloma growth need to be closely evaluated in prospective trials...
  29. ncbi request reprint Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen
    Christopher L Morris
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 120:413-23. 2003
    ..Increasing age adversely affected CD34+ yield even with limited premobilization therapy, indicating that early collection is important in elderly patients...
  30. ncbi request reprint Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression
    John Shaughnessy
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 101:3849-56. 2003
    ....
  31. ncbi request reprint A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
    John D Shaughnessy
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 109:2276-84. 2007
    ..Our data suggest that altered transcriptional regulation of genes mapping to chromosome 1 may contribute to disease progression, and that expression profiling can be used to identify high-risk disease and guide therapeutic interventions...
  32. ncbi request reprint Thrombosis in multiple myeloma
    Maurizio Zangari
    Myeloma Institute, University of Arkansas for Medical Sciences, 4301 W Markham Street, Slot 776, Little Rock, Arkansas 72205, USA
    Expert Rev Anticancer Ther 7:307-15. 2007
    ....
  33. ncbi request reprint Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy
    Giampaolo Talamo
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    J Clin Oncol 23:5217-23. 2005
    ..To assess the prevalence, time of onset, risk factors, and outcome of avascular necrosis (AVN) of bone in patients with multiple myeloma undergoing antineoplastic therapy...
  34. ncbi request reprint Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma
    Maurizio Zangari
    University of Arkansas for Medical Sciences, The Multiple Myeloma Institute for Research and Therapy, Little Rock, Arkansas, USA
    Clin Cancer Res 10:88-95. 2004
    ..SU5416 is a small molecule VEGF receptor 2 inhibitor. Experimental Design: Adult patients with advanced MM were entered on a multicenter phase II study...
  35. ncbi request reprint Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma
    Maurizio Zangari
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 131:71-3. 2005
    ..The rise in ALP after bortezomib in three patients was explained by a parallel increase in bone-specific ALP and parathyroid hormone, suggesting that response to bortezomib in myeloma is closely associated with osteoblastic activation...
  36. pmc The molecular classification of multiple myeloma
    Fenghuang Zhan
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 108:2020-8. 2006
    ..A subset of cases with a predominating myeloid gene expression signature, excluded from the profiling analyses, had more favorable baseline characteristics and superior prognosis to those lacking this signature...
  37. ncbi request reprint Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations
    Athanasios B T Fassas
    Myeloma and Transplantation Research Center, Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 117:103-8. 2002
    ..Given this universally poor prognosis, the application of allogeneic transplants should be studied in this clinical setting...
  38. pmc The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo
    Angela Pennisi
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Am J Hematol 84:6-14. 2009
    ....
  39. ncbi request reprint High-dose therapy and immunomodulatory drugs in multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Semin Oncol 29:26-33. 2002
    ..Careful scrutiny of gene expression will also help in the identification of unrecognized targets for therapeutic intervention...
  40. ncbi request reprint Hemostatic dysfunction in paraproteinemias and amyloidosis
    Maurizio Zangari
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Semin Thromb Hemost 33:339-49. 2007
    ....
  41. ncbi request reprint Clinical and biological features of multiple myeloma involving the gastrointestinal system
    Giampaolo Talamo
    Myeloma Institute for Research and Therapy, Division of Gastroenterology, The University of Arkansas for Medical Sciences, 4301 West Markham Street Slot 776, Little Rock, Arkansas 72205, USA
    Haematologica 91:964-7. 2006
    ..We conclude that MM involving the GI system is associated with adverse biological features and with short-lasting remissions, even after A high-dose chemotherapy...
  42. ncbi request reprint Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning
    Ashraf Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    J Clin Oncol 20:1295-303. 2002
    ..We present our experience with relapsed and recently diagnosed patients with high-risk multiple myeloma (MM) receiving immunosuppressive, nonmyeloablative melphalan (MEL)-based conditioning regimens (mini-allograft)...
  43. ncbi request reprint High heparanase activity in multiple myeloma is associated with elevated microvessel density
    Thomas Kelly
    Departments of Pathology, Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 7199, USA
    Cancer Res 63:8749-56. 2003
    ....
  44. ncbi request reprint Immunomodulatory drugs in multiple myeloma
    Maurizio Zangari
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Expert Opin Investig Drugs 14:1411-8. 2005
    ..Partial responses (> or = 50% reduction in M-protein) ranged from 20 to 71% in different studies depending on the pretreatment status of the patients. The combination of IMiDs with dexamethasone may be beneficial...
  45. ncbi request reprint Farnesyltransferase inhibitors and rapamycin in the treatment of multiple myeloma
    Maurizio Zangari
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Curr Pharm Biotechnol 7:449-53. 2006
    ..Farnesyltransferase inhibitors (FTIs) and rapamycin represent novel classes of signal transduction inhibitors targeting principally Ras/MAPK and PI3K/Akt pathway. Pre-clinical and early clinical reports are presented in this study...
  46. ncbi request reprint The blood coagulation mechanism in multiple myeloma
    Maurizio Zangari
    University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock, Arkansas, USA
    Semin Thromb Hemost 29:275-82. 2003
    ..The recently reported evidence of a non-factor V Leiden APC resistance has increased our understanding of the pathophysiology of this hypercoagulable state...
  47. pmc Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham, Slot 776, Little Rock, AR 72205, USA
    Haematologica 91:192-9. 2006
    ..Whereas those studies focused on the critical role of myeloma-induced osteoclastogenesis in disease progression, little is known about the impact of osteoblasts and increased bone formation on MM...
  48. ncbi request reprint Hypothyroidism in patients with multiple myeloma following treatment with thalidomide
    Ashraf Z Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Am J Med 112:412-3. 2002
  49. ncbi request reprint Anticoagulation regimens for thalidomide and lenalidomide
    Maurizio Zangari
    University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock, AR 72205, USA
    Clin Adv Hematol Oncol 4:658-9. 2006
  50. ncbi request reprint Infection--an underappreciated cause of bone pain in multiple myeloma
    Raman Desikan
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 120:1047-50. 2003
    ..Previous dexamethasone therapy, together with an episode of bacteraemia, appears to be a predisposing factor for vertebral infection. Magnetic resonance imaging enabled the diagnosis in all three patients...
  51. ncbi request reprint Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
    Fenghuang Zhan
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Blood 99:1745-57. 2002
    ..Thus, novel candidate MM disease genes have been identified using gene expression profiling and this profiling has led to the development of a gene-based classification system for MM...
  52. ncbi request reprint Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants
    Guido Tricot
    The Myeloma and Transplantation Research Center and the Division of Biometry, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 116:211-7. 2002
    ..or = 7 years and re-establishment of a monoclonal gammopathy of undetermined significance (MGUS) phase in those with persistent evidence of disease post transplantation, but without disease progression > or = 7 years...
  53. doi request reprint Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy
    Guido Tricot
    University of Utah School of Medicine, 30N 1900E, 5C402, Salt Lake City, UT 84132 USA
    Haematologica 93:1739-42. 2008
    ..001) and (v) platelet recovery was faster after first transplant (when less stem cells were infused) (p=0.01). Pegfilgrastim may be considered the standard of care for stem cell mobilization...
  54. doi request reprint Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma
    Maurizio Zangari
    Haematologica 93:953-4. 2008
  55. ncbi request reprint Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism
    Francesca Elice
    Department of Haematology, San Bortolo Hospital, Vicenza, Italy
    Br J Haematol 134:399-405. 2006
    ..This study indicates that aAPCR is the most common single transitory baseline coagulation abnormality associated with VTE in myeloma patients...
  56. pmc High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis
    Frits van Rhee
    Blood 110:827-32. 2007
    ..65, P = .003). Unlike baseline and follow-up analyses of serum and urine M-proteins, high SFLC levels at baseline-reflecting more aggressive disease-and steeper reductions after therapy identified patients with inferior survival...
  57. pmc Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis
    Fenghuang Zhan
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock 72205, USA
    Blood 109:1692-700. 2007
    ..01). The MGUS-L signature was also seen in plasma cells from 15 of 20 patients surviving more than 10 years after autotransplantation. These data provide insight into the molecular mechanisms of plasma-cell dyscrasias...
  58. ncbi request reprint Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling
    Jeffrey Haessler
    Cancer Research and Biostatistics, Seattle, Washington, USA
    Clin Cancer Res 13:7073-9. 2007
    ..To determine whether the clinical benefit of complete remission (CR) may depend on prognostic subgroups of patients with multiple myeloma...
  59. ncbi request reprint A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings
    Edward A Stadtmauer
    Hematology Oncology Division, University of Pennsylvania Health System, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Clin Adv Hematol Oncol 5:7-19, quiz 21-2. 2007
  60. ncbi request reprint Endothelial dysfunction in antiangiogenesis-associated thrombosis
    Varsha Kaushal
    J Clin Oncol 20:3042; author reply 3042-3. 2002
  61. ncbi request reprint MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants
    Joth Jacobson
    Cancer Research and Biostatistics, Seattle, WA 98101 1468, USA
    Br J Haematol 122:430-40. 2003
    ....
  62. ncbi request reprint Hyperammonemia and encephalopathy in patients with multiple myeloma
    Giampaolo Talamo
    Am J Hematol 82:414-5. 2007
  63. ncbi request reprint Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer 97:1920-8. 2003
    ..SU5416 is a small-molecule RTK inhibitor (RTKI) that targets VEGFR-2, c-kit, and fms-related tyrosine kinase Flk2...